Erratum to: Persistent complete remission of acute leukemic-phase CCR4-positive gamma–delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab (Int J Hematol, DOI 10.1007/s12185-015-1805-1;Persistent complete remission of acute leukemic-phase CCR4-positive gamma–delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab

International Journal of Hematology

Volumn 102, Issue 4, 2015, Pages 498-505

  Furukawa, Miki ^a   Ikeda, Kazuhiko ^a   Ohkawara, Hiroshi ^a   Saito, Shunichi ^a   Takahashi, Hiroshi ^a   Udea, Koki ^a   Matsumoto, Hayato ^a   Hashimoto, Yuko ^a   Ohto, Hitoshi ^a   Ogawa, Kazuei ^a   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Autologous stem cell transplantation; CCR4; Mogamulizumab; Peripheral T cell lymphoma not otherwise specified; Purging

Indexed keywords

ANTIHISTAMINIC AGENT; BLEOMYCIN; CARBOPLATIN; CHEMOKINE RECEPTOR CCR4; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LYMPHOCYTE ANTIGEN RECEPTOR; MOGAMULIZUMAB; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; CCR4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTOSIS; LYMPH NODE DISSECTION; MALE; MIDDLE AGED; MIXED CELLULARITY HODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PROTEIN EXPRESSION; RASH; REGULATORY T LYMPHOCYTE; SOUTHERN BLOTTING; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; AUTOGRAFT; BLOOD; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOGRAFTS; HUMANS; MALE; MIDDLE AGED; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, CCR4; REMISSION INDUCTION; STEM CELL TRANSPLANTATION;

EID: 84949726359     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1817-x     Document Type: Erratum

References (24)

1. The non-Hodgkin’s lymphoma classification project. A clinical evaluation of the international lymphoma study group classification of non-hodgkin’s lymphoma. Blood. 1997;89:3909–18.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
3. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–8.
4. Niedobitek G, Baumann I, Brabletz T, Lisner R, Winkelmann C, Helm G, et al. Hodgkin’s disease and peripheral T-cell lymphoma: composite lymphoma with evidence of epstein-barr virus infection. J Pathol. 2000;191:394–9.
5. Sanchez S, Holmes H, Katabi N, Newman J, Domiatti-Saad R, Stone M, et al. Composite lymphocyte-rich Hodgkin lymphoma and peripheral T-cell lymphoma associated with Epstein-Barr virus: a case report and review of the literature. Arch Pathol Lab Med. 2006;130:107–12.
6. Pajor L, Kajtár B, Jáksó P, Lacza Á, László R, Radványi G, et al. Epstein-Barr virus-induced B-cell proliferation of Hodgkin’s and Reed-Sternberg cell pheno- and genotype may develop in peripheral T-cell lymphomas. Histopathology. 2006;49:553–7.
7. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117:6756–67.
8. Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494–500.
9. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma (null) mice in vivo. J Immunol. 2009;183:4782–91.
10. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591–8.
11. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63.
12. Arcaini L, Morello L, Tucci A, Rusconi C, Ladetto M, Rattotti S, et al. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. Am J Hematol. 2015;90:230–4.
13. Ikeda K, Ohto H, Kanno T, Gonda K, Suzuki Y, Ono T, et al. Peripheral blood progenitor cell collection by two programs for autologous and allogeneic transplantation. Transfusion. 2014;54:1235–42.
14. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45:311–6.
15. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759–67.
16. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945–50.
17. Ngoma AM, Ikeda K, Hashimoto Y, Mochizuki K, Takahashi H, Sano H, et al. Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation. Int J Hematol. 2012;95:86–94.
18. Saito T, Matsuno Y, Tanosaki R, Watanabe T, Kobayashi Y, Tobinai K. gammadelta T-cell neoplasms: a clinicopathological study of 11 cases. Ann Oncol. 2002;13:1792–8.
19. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015. [Epub ahead of print].
20. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.
21. Gui L, Shi Y, He X, Lei Y, Zhang H, Han X, et al. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. Int J Hematol. 2014;99:69–78.
22. Skarbnik AP, Burki M, Pro B. Peripheral T-cell lymphomas: a review of current approaches and hopes for the future. Front Oncol. 2013;3:138.
23. Ito Y, Miyamoto T, Chong Y, Aoki T, Kato K, Akashi K, et al. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. Bone Marrow Transplant. 2013;48:998–9.
24. Belhadj K, Reyes F, Farcet J-P, Tilly H, Bastard C, Angonin R, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261–9.